Tumor aggressiveness in young women has been reported worldwide based on increases in the rate of high-grade, fast-proliferation, HR(−), basal-like and HER2-enriched breast tumors [1]–[3], [9], [13], [15], [26], [27] and their poorer overall and disease-free survival rates [5]. This evidence concerns the gene ERBB2 and breast neoplasm.